Autism Spectrum Disorder Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are fluent in English
- People who have a confirmed diagnosis of Autism Spectrum Disorder (ASD) from a clinician or clinical team, and an IQ of 70 or above
- People who are able to take part in the consent process, agree to join voluntarily, and can describe the main details of the study in their own words
- People who have been clinically stable for at least 30 days, meaning no changes to psychiatric medications or increases in dose, and no changes to other treatments during that time, as determined by a doctor
- People who score 21 or higher on a standard depression questionnaire (called the BDI-II), and whose score remains at that level over a two-week check-in period
- People who score 60 or below on a standard functioning assessment (called the GAF), and/or score below adequate functioning on another assessment (called the VABS-III), with both measured consistently over a two-week check-in period
Who may not be able to join:
- People who have had a substance use disorder (other than tobacco use) in the past six months, or who test positive for drugs at the start of the trial
- People with a serious or unstable medical or neurological condition, as determined by the study doctor
- People with metal implants or a pacemaker, or people who experience severe claustrophobia that would prevent them from having an MRI scan
- People who are actively suicidal, meaning they have a plan and intent to end their life, or who are assessed by a study psychiatrist as being at high risk of suicide
- People who have a history of seizures
- People who are taking benzodiazepine medications at a dose equivalent to 2mg or more of Lorazepam, or who are taking any anti-seizure medication
- People who have previously received rTMS (repetitive transcranial magnetic stimulation) treatment
- People who are pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stephanie H Ameis, MD, MSC, Centre for Addiction and Mental Health
Phone: 416-535-8501
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in scores on the 17-item Hamilton Rating Scale for Depression (HRSD-17)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.